Regulatory Science for Peptides

Navigate the complex landscape of peptide drug regulation — from preclinical requirements through clinical trial design and marketing authorization. This section covers global regulatory frameworks governing peptide therapeutic development.

📋

Peptide Drug Regulatory Pathways

FDA, EMA, and PMDA regulatory frameworks for peptide therapeutics, including 505(b)(2), biosimilar, and 351(a) BLA pathways.

→ FDA peptide drug classification

→ EMA advanced therapy pathways

→ Expedited approval programs

📐

ICH Guidelines for Peptide Therapeutics

International Council for Harmonisation quality, safety, and efficacy guidelines as applied to peptide drug development and manufacturing.

→ ICH Q1–Q14 quality guidelines

→ ICH S safety pharmacology

→ ICH M multidisciplinary guidelines

🏭

GMP Requirements for Peptide Manufacturing

Current Good Manufacturing Practice regulations (21 CFR 210/211, EU GMP Annex 1) specific to peptide active pharmaceutical ingredient production.

→ Facility and equipment qualification

→ Process validation requirements

→ Quality systems for peptide API

⚠️

Regulatory Control of Peptide Impurities

ICH Q3A/Q3B impurity guidelines, ICH M7 mutagenic impurities, and peptide-specific impurity control strategies.

→ Peptide-related impurity classification

→ Thresholds and qualification

→ Genotoxic impurity assessment

🔄

Biosimilar Peptides Regulatory Framework

Regulatory pathways for follow-on biologics and biosimilar peptides, including analytical similarity, comparability protocols, and interchangeability.

→ BPCI Act and biosimilar approval

→ Comparability exercise design

→ Interchangeability standards